Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-045299
Filing Date
2024-11-14
Accepted
2024-11-14 06:27:03
Documents
42
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 608057
2 ex31-1.htm EX-31.1 11317
3 ex31-2.htm EX-31.2 11187
4 ex32-1.htm EX-32.1 6933
5 ex32-2.htm EX-32.2 7020
  Complete submission text file 0001493152-24-045299.txt   3115537

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ladx-20240930.xsd EX-101.SCH 21830
7 XBRL CALCULATION FILE ladx-20240930_cal.xml EX-101.CAL 28288
8 XBRL DEFINITION FILE ladx-20240930_def.xml EX-101.DEF 104168
9 XBRL LABEL FILE ladx-20240930_lab.xml EX-101.LAB 219072
10 XBRL PRESENTATION FILE ladx-20240930_pre.xml EX-101.PRE 167925
44 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 398226
Mailing Address 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA 90049
Business Address 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA 90049 310-826-5648
LadRx Corp (Filer) CIK: 0000799698 (see all company filings)

EIN.: 581642750 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15327 | Film No.: 241456947
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)